Holen Sie sich die Stockscreener-App
23.28
1.50%
0.39
Alumis Inc Aktie (ALMS) Neueste Nachrichten
H.C. Wainwright reiterates Alumis stock rating, $25 target By Investing.com - Investing.com India
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Raymond James and Guggenheim stay bullish on Alumis (ALMS) after trial results - MSN
Quarterly Earnings: Is Alumis Inc in a consolidation phaseProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile - simplywall.st
ALUMIS INC. unveils psoriasis treatment isolating effects to immune cells only - Traders Union
Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS) - Stock Titan
Risk Analysis: Is Alumis Inc gaining market shareQuarterly Profit Review & High Return Trade Opportunity Guides - baoquankhu1.vn
Alumis Inc. (ALMS) stock price, news, quote and history - Yahoo Finance UK
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Yahoo Finance
Alumis (NASDAQ:ALMS) Shares Down 4.1%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Dropping After Good News - TipRanks
Form 8-KCurrent report - ADVFN
Why is Alumis stock falling Monday? - MSN
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans - Sahm
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - Sahm
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - MarketBeat
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - gurufocus.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - gurufocus.com
Alumis price target raised to $55 from $50 at Oppenheimer - TipRanks
Why Is Alumis Stock Falling Monday? - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - MarketBeat
Leerink reiterates Alumis stock rating on consistent trial data - Investing.com UK
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Leerink reiterates Alumis stock rating on consistent trial data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Alumis stock after trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Alumis stock after trial data - Investing.com India
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - MarketBeat
Guggenheim reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Baird reiterates Alumis stock rating on Phase 3 data strength - Investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - Investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - marketscreener.com
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - Investing.com India
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Canada
1.72%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):